Latest news with #Bulusu
Time of India
a day ago
- Business
- Time of India
D-St calling: Startups rush to file for IPOs as sensex soars
MUMBAI: IPO street is buzzing again. The strong debut of HDB Financial Services on the bourses earlier this week is expected to fire up the momentum. Startups are adding to the IPO rush: Meesho on Thursday filed its draft IPO papers with markets regulator Sebi through the confidential route, seeking to raise up to Rs 4,250 crore through a fresh issue of shares. Primary market fundraising may hit $2.4 billion in July, almost matching the $2.5 billion peak seen in Dec 2024, edging past June's $2-billion mark, said Prakash Bulusu, joint CEO at IIFL Capital. Global Tensions Ease Since last week, Pine Labs, Shadowfax, Wakefit, and Curefoods have filed their draft papers. With markets making a comeback after geopolitical tensions eased in West Asia, more startups are expediting filing of draft papers. SoftBank-backed Lenskart is expected to file draft papers in two weeks, sources said. "After a five-month lull, the resurgence in India's IPO market reflects more than pent-up supply. Confidence is returning as secondary markets stabilise, geopolitical tensions ease, and institutional risk appetite strengthens. The immediate catalyst has been the calming of global jitters combined with the smooth absorption of large block deals like the Singtel-Bharti Airtel sale. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 인터넷 최고 현금 지원 이벤트 최대 140만원 혜택 제공 인생통신 더 읽기 Undo Besides, institutional investors are back in force," said Bulusu. Big Names Look To List Too For the full year, the IPO market remains on track to raise $23-24 billion, with marquee offerings from LG Electronics India, NSDL, and JSW Cement lined up, Bulusu added. About Rs 1.7 lakh crore was raised through primary issues in 2024. From their April lows, the sensex and Nifty are up about 13%. The first batch of new-age IPOs swept the market in 2021, led by Zomato 's Rs 9,375-crore issue. The broadening of the local startup ecosystem and rising investor appetite for tech IPOs has nudged more companies in the space to tap the public markets for growth. While more than half a dozen companies, including Groww, PhysicsWallah, Boat, and Shiprocket, have filed their DRHPs since the start of the year, Zepto, PhonePe, and Oyo are among startups firming up their IPO papers. In all, some 123 companies have filed DRHPs with Sebi during Jan-June this year, against 52 firms in the same period last year, data sourced from Prime Database showed. "A flurry of issues, however, also quite often pushes through IPOs of companies which come to market at valuations that are unreasonable and end up struggling post-listing. Investors, hence, should be discerning to assess the quality of the business and valuations at IPO," said Keyur Majumdar, managing partner at Bay Capital. The IPO pipeline is very strong and ever-increasing, and the second half of the year should see a slew of IPOs, said Pranav Haldea, MD at Prime Database. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Yahoo
18-03-2025
- Business
- Yahoo
AstraZeneca director says AI must be a 'thought partner' in drug discovery
Artificial intelligence (AI) is transforming drug discovery, but its implementation must be thoughtful and strategic, according to Krishna Bulusu, senior director in oncology data science at AstraZeneca. Speaking at the ELRIG Drug Discovery meeting in London on 11 March 2025, Bulusu outlined how AI can improve efficiency, reduce costs, and support personalise medicine, but cautioned that its success depends on data integration, model explainability, and context-specific predictions. 'Accelerating drug discovery doesn't just mean doing the same thing very, very fast. It means that we're also going to do different things, and we're going to do things more efficiently,' Bulusu said. He stressed that AI should not be applied indiscriminately but should be used to answer well-defined scientific questions. One key example of how AstraZeneca is using AI role in drug discovery is the company's collaboration with biological simulation company Turbine. The partnership, announced in January 2024, uses Turbine's simulated cancer cell technology to model drug resistance mechanisms in haematological cancers. By integrating public and proprietary data, the AI-driven model generates millions of simulations, predicting drug interactions and identifying potential combination therapies. 'Now that is powerful, right?' Bulusu asked. 'Because the scalability aspect – if I have to go to the lab and do this, it'll cost me a lot of money.' Unlike traditional lab-based research, which can be time-consuming and expensive, AI simulations allow researchers to explore complex biological pathways at a fraction of the time. The model provides quantitative insights into how different inhibitors impact cellular pathways, offering a new way to generate hypotheses and refine drug development strategies. 'From a big pharma perspective, this is great because I have a portfolio of drugs, and you're telling me where to position my portfolio drugs, either as normal therapy or in combinations. That's why we work very closely with Turbine on this,' Bulusu added. The idea of AI-driven biological simulation is gaining traction across the industry. Demis Hassabis, CEO of DeepMind and co-creator of AlphaFold, has previously shared his vision for AI-powered virtual cells: 'My dream is to eventually have virtual cells, like a simulation of a virtual cell. We're maybe ten years away from that,' Hassabis said at the Financial Times Pharma and Biotech Summit in November 2024. However, Bulusu underscored that AI's success in drug discovery is not just about technological advancement but also about ensuring that models are interpretable, and predictions are relevant. 'The value for AI, at least with the larger organisations in the past, is when a non-data scientist understands and appreciates them. And this doesn't happen unless you're working together.' Despite AI's potential, significant challenges remain. Bulusu pointed to gaps in longitudinal patient data, biases in AI models, and the need for better early disease detection. 'AI needs to become a thought partner. And for that to happen, the confidence and trust in what we're doing as data scientists needs to come through,' he said. To address these challenges, Bulusu emphasised the need for improved data collection and integration, particularly capturing the full patient journey from preclinical to clinical stages. 'We are very bad as a community at generating longitudinal data,' he said. Longitudinal data needs to be colletcted before preclinical and clinical research, but this is currently happening in reverse. This is important, because Bulusu said while 'a patient's journey is very important to capture, we're just taking snapshots of it.' Looking ahead, Bulusu emphasised the importance of starting with the right scientific question before selecting an AI model. 'From an AI perspective, value and impact is and will always be driven by starting with the right question and then asking, what's the right model to answer that question. It's never the other way around,' Bulusu concluded. "AstraZeneca director says AI must be a 'thought partner' in drug discovery" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
